Results 151 to 160 of about 74,008 (304)
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz +45 more
wiley +1 more source
Summary Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies.
Julia Stomper +27 more
wiley +1 more source
Implementation of the Fluorescent in Situ Hybridization technique in the Faculty of Medicine, UdelaR
The Cytogenetic Laboratory of the Faculty of Medicine processes, on average, 300 annual samples of public and private healthcare centers by conventional cytogenetics.
Andrea Cairus +5 more
doaj
Algorithms in Allergy: Diagnosis of Hypereosinophilic Syndromes, 2026 Update
Allergy, EarlyView.
Guillaume Lefèvre +5 more
wiley +1 more source
Summary Myeloma bone disease (MBD) affects ~90% of myeloma patients, causing pain and reduced quality of life. Current anti‐resorptive treatments retard further destruction but do not repair bone. As new myeloma therapies emerge, understanding their impact on MBD is crucial.
Rebecca E. Andrews +7 more
wiley +1 more source
An optimized protocol for cytogenetics in stingless bees (Hymenoptera, Apidae, Meliponini). [PDF]
Nascimento WS +3 more
europepmc +1 more source
Plant Cytogenetics and Cytogenomics
This book provides an up-to-date account of the most widespread methods used by specialists in the field of plant cytogenetics and the emerging field of cytogenomics that will likely soon be adapted by more labs.
Heitkam, Tony, Garcia, Sònia
core +1 more source
This graphical abstract illustrates the genetic status in chronic lymphocytic leukaemia (CLL) patients with or without progression on Bruton tyrosine kinase (BTK) inhibitors. It highlights universal clonal evolution, where 100% of progressive disease cases acquired BTK or TP53 mutations.
Kiyomi Mashima +20 more
wiley +1 more source

